Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-Label, Single-Arm Study of Culmerciclib Combined With Anti-HER2 Targeted Therapy and Endocrine Therapy as Maintenance Treatment in Patients With HR-Positive, HER2-Positive Advanced Breast Cancer

NCT07732491 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07732491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07732491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-Label, Single-Arm Study of Culmerciclib Combined With Anti-HER2 Targeted Therapy and Endocrine Therapy as Maintenance Treatment in Patients With HR-Positive, HER2-Positive Advanced Breast Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2026
Completion date
December 31, 2035
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2+ advanced breast cancer, metastastic breast cancer